Lynk Pharmaceuticals collaborates with Simcere
21 March 2022 -

Lynk Pharmaceuticals Co., Ltd., a China-based clinical stage pharmaceutical company, announced on Friday that it has collaborated with Simcere (2096.HK), a China-based manufacturer and supplier of branded generic pharmaceuticals in the Chinese market, for the development and commercialisation of a highly selective JAK1 inhibitor LNK01001 in China.

According to the terms of the contract, Lynk Pharmaceuticals will be responsible for the development of the product, while Simcere will receive the exclusive rights to market the product for the indications of rheumatoid arthritis and ankylosing spondylitis in China, after completing the payment of all commercialisation rights and interests.

Lynk says that LNK01001 is a highly selective JAK1 inhibitor with therapeutic potential for various autoimmune diseases. It is conducting clinical trials in Chinese and western patient groups, including phase II studies in China in three indications of rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis. The product has previously completed Phase one clinical studies in healthy subjects in China and Australia.